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OBJECTIVE— To assess if tooth discoloration is a novel side effect of sulfonylurea therapy in
patients with permanent neonatal diabetes due to mutations in KCNJ11.
RESEARCHDESIGNANDMETHODS— A total of 67 patients with a known KCNJ11
mutation who had been successfully transferred from insulin injections onto oral sulfonylureas
were contacted and asked about the development of tooth discoloration after transfer.
RESULTS— Altered tooth appearance was identified in 5 of the 67 patients. This was variable
in severity, ranging from mild discoloration/staining (n  4) to loss of enamel (n  1) and was
only seen in patients taking glibenclamide (glyburide).
CONCLUSIONS— These previously unreported side effects may relate to the developing
tooth and/or to the high local concentrations in the children who frequently chewed gliben-
clamide tablets or took it as a concentrated solution. Given the multiple benefits of sulfonylurea
treatment for patients with activating KCNJ11 mutations, this association warrants further in-
vestigation but should not preclude such treatment.
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A ctivating mutations in KCNJ11,which encodes the Kir6.2 subunitof the ATP-sensitive potassium
(KATP) channel, are the most common
known cause of permanent neonatal di-
abetes (1,2). High-dose glibenclamide
(glyburide) allows discontinuation of
insulin and improves metabolic control
in 90% of cases (2,3). Apart from
transient diarrhea (4), no significant
side effects have been reported. We re-
port the development of tooth discolor-
ation in five patients with a KCNJ11
mutation after successful transfer onto
glibenclamide.
RESEARCH DESIGN AND
METHODS— This study was con-
ducted in accordance with the Declara-
tion of Helsinki. Informed consent was
obtained from all patients or their legal
guardians.
Genetic testing was performed at the
Peninsula Medical School, Exeter, U.K.,
or the University of Chicago, IL, as previ-
ously described (1,2). After an observa-
tion by the authors of patient 1 (see
below), the association between sulfonyl-
urea treatment and tooth discoloration
was further investigated by contacting the
referring clinicians of another 66 patients
with neonatal diabetes resulting from a
KCNJ11 mutation that had successfully
transferred onto sulfonylureas.
RESULTS— Tooth discoloration was
identified in five patients, representing
7.5% of the 67 subjects with a KCNJ11
mutation treated with sulfonylureas in the
two centers. These subjects and their ge-
notypes have previously been reported
(1–3). A summary of their clinical charac-
teristics is provided in Table 1.
Discoloration of the permanent teeth
(markedly the incisors) was noted in pa-
tient 1 6 months after transfer, while on
high-dose glibenclamide. She used to
chew the tablets. Although glibenclamide
dose was decreased to 0.6 mg  kg1 
day1 without deterioration in metabolic
control and the patient stopped chewing
the pills, there has been no improvement
in her teeth color. Patient 2 developed
loss of enamel in the upper molars and
discoloration of deciduous incisors over 4
years after transfer onto a glibenclamide
syrup (2.5 mg/ml). Interestingly, no dis-
coloration of the recently erupted perma-
nent teeth has been noted. In patient 3, a
yellowish discoloration of the deciduous
teeth was noted 1 month after transfer,
during which time the tablets were being
crushed and placed in liquid or food. A
couple of months later, she began par-
tially chewing or swallowing the tablets
whole. The discoloration resolved since
and has not recurred. Patient 4, who was
swallowing her pills, was noted about 3
months after transfer to have a plaque-like
yellowish discoloration affecting primar-
ily the front teeth. The discoloration was
easily removed by routine cleaning every
3–4 months. Patient 5 was initially dis-
solving the pills in liquid, but around the
time he began chewing the pills, he was
noted to have inconsistent grayish discolor-
ing of his deciduous teeth. This discolora-
tion was much improved after thorough
brushing of the teeth. None of the patients
reported recent changes in food intake,
drug use other than glibenclamide, family
history, or any other known risk factors
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for tooth discoloration that could explain
the association.
CONCLUSIONS— We describe five
patients with a KCNJ11 mutation devel-
oping tooth discoloration 1–55 months
after transfer from insulin onto gliben-
clamide. The severity of this novel side
effect varied from easily removable tooth
staining to nonreversible discoloration
and loss of enamel.
Tooth discoloration has not previ-
ously been described despite widespread
use of glibenclamide in adults. There are
many possible explanations for this. First,
our patients are much younger than pa-
tients with type 2 diabetes, and tooth dis-
coloration is more noticeable in white
deciduous than in the permanent teeth,
which tend to be darker. Second, the
doses used in children are usually higher
than the maximum doses used in adults
(3). However, there seems to be no clear
relationship between glibenclamide dose
and the development of tooth discolora-
tion within our cohort, since patient 2 was
on a low dose (0.1 mg  kg1  day1), and
no tooth discoloration was noted in a fur-
ther 62 patients with KCNJ11 diabetes
who were successfully managed on simi-
lar doses of sulfonylureas. Third, and
most likely, the teeth may have been ex-
posed to high local concentrations of glib-
enclamide because of tablets being
chewed or taken in solution. In keeping
with this, most evidence indicates that the
cause of tooth staining is the precipitation
of ingested chromogens onto dental sur-
face (5). However, the possible patho-
genic mechanism for the more severe
effect on enamel seen in patient 2 remains
unclear. Many other pediatric liquid medi-
caments have an erosive effect on the pri-
mary enamel surface (6). In addition to this
local effect, it may relate to a decrease in
blood flow to the teeth, since glibenclamide,
a nonselective sulfonylurea, reduces blood
flow to the dental pulp by 70% (7) by acting
on vascular KATP channels (composed of
Kir6.1 and SUR2B) (8). It might also be pos-
sible that loss of enamel is unrelated to sul-
fonylurea therapy, since it was present in
deciduous teeth but not in permanent teeth.
Clinicians should be aware of this
novel side effect of glibenclamide therapy
in patients with neonatal diabetes result-
ing from a KCNJ11 mutation. While the
cause is uncertain, patients should prob-
ably be advised not to chew tablets. Al-
though the effect seems to have mainly a
cosmetic consequence and should thus
not preclude such treatment, this previ-
ously unreported association warrants
further investigation.
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